File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Aberrant methylation of cyclooxygenase-2 in breast cancer patients

TitleAberrant methylation of cyclooxygenase-2 in breast cancer patients
Authors
Issue Date2005
PublisherElsevier France, Editions Scientifiques et Medicales. The Journal's web site is located at http://www.elsevier.com/locate/biopha
Citation
Proceedings of the 1st Annual Conference of OOTR COX-2 and Angiogenesis in Oncology, Hong Kong, 15-16 October 2004. In Biomedicine & Pharmacotherapy, 2005, v. 59 n. suppl. 2, p. S264-S267 How to Cite?
AbstractBACKGROUND: Although aberrant CpG island methylation and subsequent silencing of the cyclooxygenase-2 (COX-2) promoter has been observed in colorectal and gastric tumors recently, little is known about that in breast cancers. The aim of this study was to identify the methylation status of COX-2 as well as to determine the association between clinical characteristics and COX-2 methylation in breast cancer patients. METHODS: Using bisulfite modification and a methylation-specific PCR, we examined the methylation status of the COX-2 promoter in primary tumors from 110 breast cancer patients. Meanwhile, the expression of COX-2 protein was determined by immunohistochemistry (IHC). RESULTS: Twenty out of 110 (18.2%) primary breast cancers showed aberrant methylation of the 5' region of COX-2. Loss of expression of COX-2 protein was found in all tumors with COX-2 methylation. Methylation of COX-2 was strongly correlated with tumor size (P = 0.026), presence of axillary lymph node metastasis (P = 0.001) and lymphovascular permeation (P = 0.034). CONCLUSION: Our data suggest that COX-2 methylation is associated with good prognostic factors in breast cancer patients. COX-2 promoter methylation may be one of the mechanisms by which tumor cells regulate COX-2 expression.
Persistent Identifierhttp://hdl.handle.net/10722/211380
ISSN
2015 Impact Factor: 2.326
2015 SCImago Journal Rankings: 0.787
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChow, LWC-
dc.contributor.authorZhu, L-
dc.contributor.authorLoo, WTY-
dc.contributor.authorLui, ELH-
dc.date.accessioned2015-07-09T04:14:46Z-
dc.date.available2015-07-09T04:14:46Z-
dc.date.issued2005-
dc.identifier.citationProceedings of the 1st Annual Conference of OOTR COX-2 and Angiogenesis in Oncology, Hong Kong, 15-16 October 2004. In Biomedicine & Pharmacotherapy, 2005, v. 59 n. suppl. 2, p. S264-S267-
dc.identifier.issn0753-3322-
dc.identifier.urihttp://hdl.handle.net/10722/211380-
dc.description.abstractBACKGROUND: Although aberrant CpG island methylation and subsequent silencing of the cyclooxygenase-2 (COX-2) promoter has been observed in colorectal and gastric tumors recently, little is known about that in breast cancers. The aim of this study was to identify the methylation status of COX-2 as well as to determine the association between clinical characteristics and COX-2 methylation in breast cancer patients. METHODS: Using bisulfite modification and a methylation-specific PCR, we examined the methylation status of the COX-2 promoter in primary tumors from 110 breast cancer patients. Meanwhile, the expression of COX-2 protein was determined by immunohistochemistry (IHC). RESULTS: Twenty out of 110 (18.2%) primary breast cancers showed aberrant methylation of the 5' region of COX-2. Loss of expression of COX-2 protein was found in all tumors with COX-2 methylation. Methylation of COX-2 was strongly correlated with tumor size (P = 0.026), presence of axillary lymph node metastasis (P = 0.001) and lymphovascular permeation (P = 0.034). CONCLUSION: Our data suggest that COX-2 methylation is associated with good prognostic factors in breast cancer patients. COX-2 promoter methylation may be one of the mechanisms by which tumor cells regulate COX-2 expression.-
dc.languageeng-
dc.publisherElsevier France, Editions Scientifiques et Medicales. The Journal's web site is located at http://www.elsevier.com/locate/biopha-
dc.relation.ispartofBiomedicine & Pharmacotherapy-
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in [Journal title]. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in PUBLICATION, [VOL#, ISSUE#, (DATE)] DOI#-
dc.subject.meshBreast Neoplasms - enzymology-
dc.subject.meshCpG Islands - genetics-
dc.subject.meshCyclooxygenase 2 - metabolism-
dc.subject.meshDNA, Neoplasm - genetics-
dc.subject.meshGene Silencing-
dc.titleAberrant methylation of cyclooxygenase-2 in breast cancer patients-
dc.typeConference_Paper-
dc.identifier.emailChow, LWC: lwcchow@hkucc.hku.hk-
dc.identifier.emailZhu, L: zhuli@graduate.hku.hk-
dc.identifier.emailLoo, WTY: tyloo@hkucc.hku.hk-
dc.identifier.emailLui, ELH: h0148841@hkusua.hku.hk-
dc.identifier.doi10.1016/S0753-3322(05)80042-3-
dc.identifier.pmid16507389-
dc.identifier.scopuseid_2-s2.0-33644601609-
dc.identifier.hkuros114688-
dc.identifier.volume59-
dc.identifier.issuesuppl. 2-
dc.identifier.spageS264-
dc.identifier.epageS267-
dc.identifier.isiWOS:000234423600002-
dc.publisher.placeFrance-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats